Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epitopes, T-Lymphocyte | 3 | 2022 | 45 | 1.710 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2022 | 64 | 1.480 |
Why?
|
| Antigen Presentation | 6 | 2023 | 78 | 1.120 |
Why?
|
| West Nile virus | 3 | 2016 | 20 | 1.070 |
Why?
|
| HLA-DR Antigens | 2 | 2023 | 29 | 1.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2022 | 91 | 0.890 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2022 | 58 | 0.820 |
Why?
|
| Immunodominant Epitopes | 2 | 2016 | 13 | 0.650 |
Why?
|
| Antigens, Neoplasm | 4 | 2022 | 50 | 0.540 |
Why?
|
| West Nile Fever | 1 | 2013 | 15 | 0.440 |
Why?
|
| Peptide Fragments | 1 | 2013 | 197 | 0.390 |
Why?
|
| Dendritic Cells | 4 | 2019 | 142 | 0.370 |
Why?
|
| Peptides | 4 | 2023 | 280 | 0.370 |
Why?
|
| HLA-DQ Antigens | 2 | 2023 | 25 | 0.270 |
Why?
|
| Melanoma | 2 | 2019 | 140 | 0.260 |
Why?
|
| HLA-A2 Antigen | 2 | 2015 | 17 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2016 | 75 | 0.240 |
Why?
|
| Ligands | 2 | 2022 | 168 | 0.230 |
Why?
|
| Mass Spectrometry | 2 | 2022 | 186 | 0.220 |
Why?
|
| Protein Binding | 2 | 2022 | 631 | 0.210 |
Why?
|
| Melanoma, Experimental | 1 | 2022 | 29 | 0.210 |
Why?
|
| Databases, Protein | 1 | 2022 | 22 | 0.200 |
Why?
|
| Neoplasms | 2 | 2022 | 756 | 0.190 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 162 | 0.190 |
Why?
|
| Cell Line | 1 | 2022 | 672 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 11 | 0.170 |
Why?
|
| Humans | 10 | 2023 | 26846 | 0.170 |
Why?
|
| Cancer Vaccines | 2 | 2019 | 32 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 56 | 0.160 |
Why?
|
| Antibody Specificity | 2 | 2016 | 113 | 0.160 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 274 | 0.160 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 1263 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 316 | 0.140 |
Why?
|
| Mutation | 2 | 2017 | 820 | 0.130 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 24 | 0.130 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2015 | 8 | 0.130 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2015 | 8 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 264 | 0.130 |
Why?
|
| Immunotherapy, Active | 1 | 2015 | 6 | 0.120 |
Why?
|
| Mice | 3 | 2022 | 4406 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 128 | 0.110 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 54 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 129 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 128 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 377 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2013 | 282 | 0.100 |
Why?
|
| Female | 4 | 2017 | 14466 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2013 | 503 | 0.100 |
Why?
|
| HLA Antigens | 2 | 2023 | 57 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2022 | 135 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2013 | 970 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 563 | 0.080 |
Why?
|
| Animals | 3 | 2022 | 9962 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2019 | 20 | 0.070 |
Why?
|
| Amino Acid Substitution | 2 | 2019 | 102 | 0.070 |
Why?
|
| Monitoring, Immunologic | 2 | 2017 | 7 | 0.070 |
Why?
|
| Young Adult | 1 | 2013 | 2582 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 1475 | 0.060 |
Why?
|
| HLA-DP Antigens | 1 | 2023 | 3 | 0.060 |
Why?
|
| Aged | 1 | 2013 | 5168 | 0.050 |
Why?
|
| Acetylglucosamine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Machine Learning | 1 | 2023 | 79 | 0.050 |
Why?
|
| Middle Aged | 1 | 2013 | 6820 | 0.050 |
Why?
|
| Male | 2 | 2017 | 12874 | 0.050 |
Why?
|
| Adult | 1 | 2013 | 7384 | 0.050 |
Why?
|
| Major Histocompatibility Complex | 1 | 2020 | 27 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2019 | 3 | 0.040 |
Why?
|
| Clone Cells | 1 | 2019 | 20 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2019 | 8 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 33 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2019 | 9 | 0.040 |
Why?
|
| Vaccination | 1 | 2019 | 167 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 364 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2017 | 206 | 0.040 |
Why?
|
| Proteome | 1 | 2017 | 75 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 544 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2017 | 221 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2015 | 12 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 340 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2014 | 10 | 0.030 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 10 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2014 | 42 | 0.030 |
Why?
|